DE60331778D1 - Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität - Google Patents

Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität

Info

Publication number
DE60331778D1
DE60331778D1 DE60331778T DE60331778T DE60331778D1 DE 60331778 D1 DE60331778 D1 DE 60331778D1 DE 60331778 T DE60331778 T DE 60331778T DE 60331778 T DE60331778 T DE 60331778T DE 60331778 D1 DE60331778 D1 DE 60331778D1
Authority
DE
Germany
Prior art keywords
myostatin
activation
metalloprotease
agent
decreasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331778T
Other languages
English (en)
Inventor
Se-Jin Lee
Alexandra C Mcpherron
Daniel S Greenspan
William N Pappano
Neil Wolfman
Kathy Tomkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Johns Hopkins University
Wisconsin Alumni Research Foundation
Original Assignee
Wyeth LLC
Johns Hopkins University
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC, Johns Hopkins University, Wisconsin Alumni Research Foundation filed Critical Wyeth LLC
Application granted granted Critical
Publication of DE60331778D1 publication Critical patent/DE60331778D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE60331778T 2002-09-16 2003-09-16 Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität Expired - Lifetime DE60331778D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41113302P 2002-09-16 2002-09-16
US43916403P 2003-01-09 2003-01-09
US48686303P 2003-07-10 2003-07-10
PCT/US2003/029079 WO2004024890A2 (en) 2002-09-16 2003-09-16 Metalloprotease activation of myostatin, and methods of modulating myostatin activity

Publications (1)

Publication Number Publication Date
DE60331778D1 true DE60331778D1 (de) 2010-04-29

Family

ID=31999236

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331778T Expired - Lifetime DE60331778D1 (de) 2002-09-16 2003-09-16 Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität

Country Status (12)

Country Link
US (3) US20040138118A1 (de)
EP (3) EP1549747A4 (de)
JP (3) JP2006507356A (de)
AT (1) ATE461275T1 (de)
AU (3) AU2003267246A1 (de)
BR (2) BR0314270A (de)
CA (2) CA2498044A1 (de)
DE (1) DE60331778D1 (de)
ES (1) ES2344734T3 (de)
IL (1) IL166651A (de)
MX (2) MXPA05002648A (de)
WO (2) WO2004024890A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
IL163525A0 (en) * 2002-02-21 2005-12-18 Wyeth Corp A follistatin domain containing protein
KR20040096592A (ko) * 2002-02-21 2004-11-16 와이어쓰 폴리스타틴 도메인을 포함하는 단백질
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
CA2498044A1 (en) * 2002-09-16 2004-03-25 Wyeth Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
BRPI0410927A (pt) * 2003-06-02 2006-06-27 Wyeth Corp métodos terapêuticos e profiláticos para distúrbios neuromusculares
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
US20080118487A1 (en) * 2004-09-30 2008-05-22 Orico Limited Myostatin Isoform
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
BRPI0609449A2 (pt) * 2005-03-23 2010-04-06 Wyeth Corp detecção de agentes de modulação de gdf-8
WO2006107611A2 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to gdf-8 modulating agents
EP1951756B1 (de) * 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin-antikörper
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
EP1880731A1 (de) * 2006-07-18 2008-01-23 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Menschlicher Wachstums und Differenzierungsfaktor GDF-5
EP2518496A3 (de) 2006-07-21 2013-02-27 GENERA ISTRAZIVANJA d.o.o. BMP-1-Procollagen-C-Proteinase zur Diagnose und Behandlung von Beschädigungen und Erkrankungen an Knochen und Weichgeweben
AU2012200193B2 (en) * 2006-07-21 2015-04-09 Genera Istrazivanja D.O.O. BMP-1 procollagen C-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders
CA2693378C (en) 2006-08-03 2020-04-14 Orico Limited Myostatin antagonists
KR101123531B1 (ko) * 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
ES2358028B1 (es) * 2009-10-19 2011-11-28 Universidade De Santiago De Compostela Procedimiento de obtención de catalizadores híbridos compuestos por complejos de metales de transición encapsulados en nanopartículas porosas de sílice, titania o circonia.
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
WO2014039189A1 (en) 2012-08-01 2014-03-13 Mcnally Elizabeth Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
EP3597747B1 (de) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Maus-fgcgammarii-spezifischer fc-antikörper
JP6501521B2 (ja) 2012-08-24 2019-04-17 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法
US9844531B2 (en) 2013-03-15 2017-12-19 Abbott Laboratories Methods of maintaining and improving muscle function
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
UA118278C2 (uk) 2014-01-10 2018-12-26 Глаксосмітклайн Інтеллектьюел Проперті (№ 2) Лімітед Гідроксиформамідні похідні та їх застосування
TWI593967B (zh) * 2014-05-01 2017-08-01 高雄醫學大學 二級抗體所辨識之抗原決定位及其用途
EP3215175A4 (de) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latentes-myostatin-antikörper und verwendungen davon
TWI779010B (zh) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
RS62330B1 (sr) 2015-09-15 2021-10-29 Scholar Rock Inc Antitela pro/latentnog miostatina i njihova upotreba
WO2017075037A1 (en) * 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2017206069A1 (en) 2016-01-08 2018-07-19 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
DK3368069T3 (da) 2016-06-13 2020-11-02 Scholar Rock Inc Anvendelse af myostatininhibitorer og kombinationsterapier
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
HRP20230308T1 (hr) 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
JP2022514778A (ja) 2018-12-21 2022-02-15 ノースウェスタン ユニバーシティ 筋膜損傷の予防および治療におけるアネキシンの使用
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20220354817A1 (en) * 2019-09-24 2022-11-10 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia containing non-natural amino acid derivative

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591227B1 (fr) * 1985-12-06 1988-11-10 Pasteur Institut Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
EP0690873B1 (de) * 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Wachstumsfaktor-8
KR100227406B1 (ko) * 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 조성물
KR100329409B1 (ko) * 1993-08-26 2002-03-20 브루스 엠. 에이센, 토마스 제이 데스로저 인간 골 형태발생 단백질을 사용한 신경 재생법
WO1996001845A1 (en) * 1994-07-08 1996-01-25 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
KR20040096592A (ko) * 2002-02-21 2004-11-16 와이어쓰 폴리스타틴 도메인을 포함하는 단백질
IL163525A0 (en) * 2002-02-21 2005-12-18 Wyeth Corp A follistatin domain containing protein
CA2498044A1 (en) * 2002-09-16 2004-03-25 Wyeth Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
PT1581649E (pt) * 2002-12-20 2011-04-13 Amgen Inc Agentes de ligação que inibem a miostatina
JP2005042091A (ja) * 2003-07-04 2005-02-17 Nitto Denko Corp 電気絶縁材料用ポリイミド樹脂

Also Published As

Publication number Publication date
BR0314270A (pt) 2005-08-02
EP1549747A4 (de) 2006-08-23
EP1578928A2 (de) 2005-09-28
JP2010248195A (ja) 2010-11-04
CA2496213C (en) 2013-11-19
JP4547561B2 (ja) 2010-09-22
US20060275280A1 (en) 2006-12-07
IL166651A0 (en) 2006-01-15
WO2004024092A3 (en) 2004-08-26
MXPA05002968A (es) 2005-09-08
ATE461275T1 (de) 2010-04-15
AU2003267246A1 (en) 2004-04-30
WO2004024890A2 (en) 2004-03-25
EP2192129A1 (de) 2010-06-02
ES2344734T3 (es) 2010-09-06
US20040138118A1 (en) 2004-07-15
EP1578928B1 (de) 2010-03-17
WO2004024092A2 (en) 2004-03-25
EP1578928A4 (de) 2007-01-03
BR0314380A (pt) 2005-07-19
EP1549747A2 (de) 2005-07-06
JP5369044B2 (ja) 2013-12-18
US20050043232A1 (en) 2005-02-24
IL166651A (en) 2013-12-31
AU2003272394A1 (en) 2004-04-30
JP2006517525A (ja) 2006-07-27
US7572599B2 (en) 2009-08-11
JP2006507356A (ja) 2006-03-02
CA2498044A1 (en) 2004-03-25
MXPA05002648A (es) 2005-08-19
CA2496213A1 (en) 2004-03-25
WO2004024890A3 (en) 2006-07-27
AU2010201977A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
DE60331778D1 (de) Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
DE60035163D1 (de) Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
DE69817211D1 (de) Charakterisierung von polypeptiden
ATE420947T1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
ATE317908T1 (de) Verfahren zur herstellung von rekombinanten viren
DE60027551D1 (de) Zusammensetzungen und verfahren zur regulierung des serumcholesterins
MX9101526A (es) Nuevo metodo para tratar la depresion
DE60134230D1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
DE69938451D1 (de) Fas peptide und antikörper zur modulierung von apoptosis
ATE185146T1 (de) Verfahren zur entfernung von n-terminalem methionin
DE60238449D1 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
DE50114193D1 (de) Verfahren zur identifizierung von substanzen, die die aktivität von hyperpolarisations-aktivierten kationen-kanälen modulieren
DE19881185D2 (de) Vorrichtung zur Zerstörung bzw. Zertrümmerung von Konkrementen
ATE506073T1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
ATE330011T1 (de) Bevorzugte segmente des ntp-proteins (neural thread protein) und verfahren zu deren verwendung
ATE416260T1 (de) Verfahren zur überwachung und modulierung von proteinfaltung
WO2003074007A3 (en) Modulators of leukocyte activation, compositions, and methods of use
ES2173888T3 (es) Nueva proteasa.
DE29601518U1 (de) Vorrichtung zur Vermittlung von Informationen über den Bewegungsablauf von Fahrzeugen
WO2002055707A3 (en) Cloning of an inhibitor of antigen-receptor signaling by a retroviral-based functional screen
WO2001067097A3 (en) Method of identifying modulators of presenilin
DE59914155D1 (de) Neue peptidfragmente zur reinigung von proteinen
EP1428893A3 (de) Verfahren und Zusammensetzungen zur Modulierung des Haarwachstums durch p-Cadherin-Modulatoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition